Moore Terry W, Mayne Christopher G, Katzenellenbogen John A
Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA.
Mol Endocrinol. 2010 Apr;24(4):683-95. doi: 10.1210/me.2009-0362. Epub 2009 Nov 20.
Because of their central importance in gene regulation and mediating the actions of many hormones, the nuclear receptors (NRs) have long been recognized as very important biological and pharmaceutical targets. Of all the surfaces available on a given NR, the singular site for regulation of receptor activity has almost invariably been the ligand-binding pocket of the receptor, the site where agonists, antagonists, and selective NR modulators interact. With our increasing understanding of the multiple molecular components involved in NR action, researchers have recently begun to look to additional interaction sites on NRs for regulating their activities by novel mechanisms. The alternate NR-associated interaction sites that have been targeted include the coactivator-binding groove and allosteric sites in the ligand-binding domain, the zinc fingers of the DNA-binding domain, and the NR response element in DNA. The studies thus far have been performed with the estrogen receptors, the androgen receptor (AR), the thyroid hormone receptors, and the pregnane X receptor. Phenotypic and conformation-based screens have also identified small molecule modulators that are believed to function through the NRs but have, as yet, unknown sites and mechanisms of action. The rewards from investigation of these NR alternate-site modulators should be the discovery of new therapeutic approaches and novel agents for regulating the activities of these important NR proteins.
由于核受体(NRs)在基因调控以及介导多种激素作用方面具有核心重要性,长期以来它们一直被视为非常重要的生物学和药物靶点。在给定的核受体上所有可利用的表面中,几乎无一例外,调节受体活性的唯一部位一直是受体的配体结合口袋,即激动剂、拮抗剂和选择性核受体调节剂相互作用的部位。随着我们对参与核受体作用的多种分子成分的了解不断增加,研究人员最近开始寻找核受体上的其他相互作用位点,以通过新机制调节其活性。已被靶向的其他与核受体相关的相互作用位点包括配体结合域中的共激活因子结合凹槽和别构位点、DNA结合域的锌指以及DNA中的核受体反应元件。迄今为止,这些研究是针对雌激素受体、雄激素受体(AR)、甲状腺激素受体和孕烷X受体进行的。基于表型和构象的筛选也鉴定出了一些小分子调节剂,据信它们通过核受体发挥作用,但作用位点和作用机制尚不清楚。研究这些核受体替代位点调节剂有望发现新的治疗方法和新型药物,用于调节这些重要核受体蛋白的活性。